Skip to content

Clinical trial data for midostaurin (PKC412) in advanced systemic mastocytosis has been published

Hey, everyone –

I know a lot of people have been waiting with bated breath for the outcome of the trial assessing the use of midostaurin (PKC412) in advanced systemic mastocytosis (a term describing aggressive systemic mastocytosis, mast cell leukemia, and systemic mastocytosis with associated clonal hematologic non-mast cell lineage disease).

A press release described the outcome of the phase II trial. Read it here.

Data from the phase II trial was also published. Read it here.

Please note that because of my job, I cannot answer questions about this medication.